TITLE:
Some Oxidative Stress Biomarkers among Patients with Prostate Cancer in Sokoto, North Western Nigeria
AUTHORS:
Osaro Erhabor, Asmau Muhammad Hussaini, Abdullahi Abdulwahab-Ahmed, Michael Retsky, Tosan Erhabor
KEYWORDS:
Some Oxidative Stress Biomarkers, Prostate Cancer, Sokoto, North Western Nigeria
JOURNAL NAME:
Open Journal of Blood Diseases,
Vol.12 No.3,
September
16,
2022
ABSTRACT: Globally, prostate cancer (PCa) is the most common malignancy and the second
leading cause of cancer-related death in men. It is a significant contributor
to the burden of diseases and affects over a million men. This study investigated
the levels of malondialdehyde and plasma total antioxidant capacity among
patients with prostate cancer in Sokoto. This case-control study was conducted
among 28 confirmed prostate cancer patients attending the Urology clinics in
Usmanu Danfodiyo University Teaching Hospital and Sokoto Specialist Hospital in North Western Nigeria. Twenty-eight age-matched healthy males were monitored as controls. Determination of Total Antioxidant
Capacity (TAC) was determined using Ferric Reducing Antioxidant Power (FRAP)
reagent while the Malondialdehyde in serum was determined as a conjugate with
Thiobarbituric acid (TBA) acid. Data were collected using a semi-structured interviewer-administered
questionnaire. Data were processed using SPSS version 20 and results
were reported as Mean ± Standard deviation. The malondialdehyde level was
significantly increased (p s evidence of redox imbalance. Subjects in monogamous relationships compared to polygamous, rural dwellers, farmers, individuals of Hausa ethnicity
and subjects who reported no family history of the disease were more predisposed
to prostate cancer. Further epidemiological studies are needed to determine the
predisposing factors and the potential role of these markers in the diagnosis,
prognosis and management of prostate cancer patients in Sokoto in particular
and Nigeria in general. We recommend that Malondialdehyde and Total Antioxidant
Capacity be routinely monitored among patients with prostate cancer patients in
the area.